Non-small cell lung cancer
Conditions
Interventions
docetaxel/cisplatin/bevacizumab combination therapy
Sponsors
Thoracic Oncology Research Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) pathologically diagnosed non-squamous non-small cell cancer 2) stage III/IV without indication for curative radiothrapy or post-operative reccurent disease 3) aged 20 years or older, under 75 years 4) ECOG PS: 0-1 5) measurable lesion meeting RECIST criteria (version 1.1) 6) no prior treatment except for surgery,EGFR-TKI, palliative radiotherapy 7) adequate organ function 8) life expectancy more than 3 months 9) adequate interval after prior treatments; 2 weeks from radiotherapy, 8 weeks from lobectomy, 4 weeks from exploratory thoracotomy, 2 weeks pleural drainage 10) written informed consent
Exclusion criteria
Exclusion criteria: 1) brain metastasis 2) histroy of hemoptysis 3) serious complication; cardiac disea se, interstitial peumonia, diabetes, active infection 4) massive pleural or pericardial effusion, ascites 5) concomitant malignancy 6) uncontrollable peptic ulcer or GI perforaion within 1 year 7) uncontrollable hypertension 8) anticoagulation therapy 9) inappropriate for this study judged by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse events, progression free survival, overall survival | — |
Countries
Japan
Contacts
Public ContactTerufumi Kato
Kanagawa Cardiovascular and Respiratory Center Department of Respiratory Medicine
Outcome results
None listed